RIGEL PHARMACEUTICALS INC Form 8-K February 10, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2006

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-29889 (Commission File No.)


94-3248524 (IRS Employer Identification No.)

1180 Veterans Boulevard

South San Francisco, CA 94080

(Address of principal executive offices and zip code)

Registrant s telephone number, including area code: (650) 624-1100



ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 7, 2006, Rigel Pharmaceuticals, Inc. announced certain financial results for its fourth quarter and year ended December 31, 2005. A copy of Rigel s press release, entitled Rigel Announces Fourth Quarter and Year End 2005 Financial Results, is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release, dated February 7, 2006, entitled Rigel Announces Fourth Quarter and Year End 2005 Financial Results.

The information in this report, including the exhibit hereto, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Rigel Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RIGEL PHARMACEUTICALS, INC.

Dated: February 9, 2006

By: /s/ Dolly Vance

Dolly Vance

General Counsel and Vice President of Intellectual

Property

3

EXHIBIT INDEX

Exhibit No.	Description	
99.1	Press Release, dated February 7, 2006, entitled Rigel Announces Fourth Quarter and Year End 2005 Financial Results.	sults.
	4	
	7	